Tobacco Treatment in the Context of Lung Cancer Screening

Medical University of South Carolina48 enrolled

Overview

The proposed study will test a medication plus text messaging intervention specifically designed for lung cancer screening patients. Half of the patients will receive standard of care, and half will receive the treatment intervention.

Screening for lung cancer at earlier, more treatable stages has the potential to reduce mortality from the U.S.'s most deadly cancer. Annual lung cancer screening with low-dose computed tomography is now recommended for high risk individuals based on age and smoking history. This study will evaluate a smoking cessation intervention for lung cancer screening patients. We will evaluate quit rates after a standard intervention (brief counseling session at time of lung cancer screening) versus a dual nicotine replacement therapy (NRT) and gain-framed text messaging intervention.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Smoking Cessation

Interventions

Text messaging plus nicotine replacement therapyBEHAVIORAL

Brief advice to quit smoking prior to lung cancer screening (LCS), 8 weeks of gain-framed, LCS-tailored text messages, and nicotine replacement therapy.

Standard Care at Lung Cancer ScreeningOTHER

Brief advice to quit smoking prior to lung cancer screening

Eligibility

Sex: ALLMin age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion: 1. 55 years or older 2. 30 pack year history of smoking 3. current smoker (defined as breath carbon monoxide\>6ppm) 4. willing to be randomized 5. English speaking Exclusion: 1. unstable psychiatric/medical conditions such as suicidal ideation, acute psychosis, severe alcohol dependence, substance abuse, or dementia 2. in the immediate (within 2 weeks) post myocardial infarction period 3. serious arrhythmias 4. unstable angina pectoris 5. hemodynamically or electrically unstable 6. currently taking part in any other tobacco treatment program or using cessation medication (i.e., taking NRT or other cessation medications, enrolled in the Quitline, in another drug study).

Locations (1)

Medical University of South Carolina

Charleston, South Carolina, United States

Outcomes

Primary Outcomes

End of Treatment Abstinence Rates

7-day point prevalence abstinence

Time frame: Week 8 (end of treatment)

Secondary Outcomes

End of Study Abstinence Rates

Effect size estimates at End of Study

Time frame: 3-month follow-up

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.